Do analysts rate BNR or ABEO?

Abeona Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 164.44%. Given Abeona Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Abeona Therapeutics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Abeona Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts rate BNR or IPSC?

Century Therapeutics has a consensus price target of $4.75, suggesting a potential upside of 136.91%. Given Century Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Century Therapeutics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Century Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Do analysts rate BNR or AKBA?

Akebia Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 336.55%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Akebia Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts prefer BNR or ELYM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer DMAC or BNR?

DiaMedica Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 77.65%. Given DiaMedica Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe DiaMedica Therapeutics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DiaMedica Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Burning Rock Biotech (BNR) Competitors

$10.24 +1.43 (+16.19%)

As of 11:16 AM Eastern

Compare

BNR vs. ABEO, IPSC, AKBA, ELYM, and DMAC

Should you buy Burning Rock Biotech stock or one of its competitors? MarketBeat compares Burning Rock Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Burning Rock Biotech include Abeona Therapeutics (ABEO), Century Therapeutics (IPSC), Akebia Therapeutics (AKBA), Eliem Therapeutics (ELYM), and DiaMedica Therapeutics (DMAC). These companies are all part of the "biotechnology" industry.

How does Burning Rock Biotech compare to Abeona Therapeutics?

Burning Rock Biotech (NASDAQ:BNR) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Comparatively, 7.1% of Abeona Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Abeona Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 164.44%. Given Abeona Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Abeona Therapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Abeona Therapeutics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -11.57%. Burning Rock Biotech's return on equity of -10.98% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
Abeona Therapeutics	N/A	-53.98%	-38.52%

Burning Rock Biotech has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

In the previous week, Abeona Therapeutics had 4 more articles in the media than Burning Rock Biotech. MarketBeat recorded 4 mentions for Abeona Therapeutics and 0 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.00 equaled Abeona Therapeutics'average media sentiment score.

Company	Overall Sentiment
Burning Rock Biotech	Neutral
Abeona Therapeutics	Neutral

Abeona Therapeutics has lower revenue, but higher earnings than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.40	-$7.92M	-$0.82	N/A
Abeona Therapeutics	$5.82M	70.36	$71.18M	$0.97	7.41

Summary

Abeona Therapeutics beats Burning Rock Biotech on 11 of the 15 factors compared between the two stocks.

How does Burning Rock Biotech compare to Century Therapeutics?

Burning Rock Biotech (NASDAQ:BNR) and Century Therapeutics (NASDAQ:IPSC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Burning Rock Biotech has higher earnings, but lower revenue than Century Therapeutics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.40	-$7.92M	-$0.82	N/A
Century Therapeutics	$109.16M	3.31	-$9.58M	-$1.14	N/A

Burning Rock Biotech has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market.

Century Therapeutics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -11.57%. Burning Rock Biotech's return on equity of -10.98% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
Century Therapeutics	N/A	-49.89%	-37.42%

In the previous week, Century Therapeutics had 3 more articles in the media than Burning Rock Biotech. MarketBeat recorded 3 mentions for Century Therapeutics and 0 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.00 equaled Century Therapeutics'average media sentiment score.

Company	Overall Sentiment
Burning Rock Biotech	Neutral
Century Therapeutics	Neutral

Century Therapeutics has a consensus price target of $4.75, suggesting a potential upside of 136.91%. Given Century Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Century Therapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by company insiders. Comparatively, 2.4% of Century Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Century Therapeutics beats Burning Rock Biotech on 10 of the 15 factors compared between the two stocks.

How does Burning Rock Biotech compare to Akebia Therapeutics?

Burning Rock Biotech (NASDAQ:BNR) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Burning Rock Biotech has a net margin of -11.57% compared to Akebia Therapeutics' net margin of -13.54%. Burning Rock Biotech's return on equity of -10.98% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

Burning Rock Biotech has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market.

In the previous week, Akebia Therapeutics had 20 more articles in the media than Burning Rock Biotech. MarketBeat recorded 20 mentions for Akebia Therapeutics and 0 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 0.00 beat Akebia Therapeutics' score of -0.02 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Burning Rock Biotech	Neutral
Akebia Therapeutics	Neutral

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Akebia Therapeutics has higher revenue and earnings than Burning Rock Biotech. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.40	-$7.92M	-$0.82	N/A
Akebia Therapeutics	$236.20M	1.01	-$5.34M	-$0.11	N/A

Akebia Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 336.55%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Akebia Therapeutics beats Burning Rock Biotech on 9 of the 16 factors compared between the two stocks.

How does Burning Rock Biotech compare to Eliem Therapeutics?

Burning Rock Biotech (NASDAQ:BNR) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Burning Rock Biotech has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the broader market.

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Burning Rock Biotech has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Burning Rock Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.40	-$7.92M	-$0.82	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Eliem Therapeutics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -11.57%. Burning Rock Biotech's return on equity of -10.98% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
Eliem Therapeutics	N/A	-47.03%	-45.97%

In the previous week, Burning Rock Biotech's average media sentiment score of 0.00 equaled Eliem Therapeutics'average media sentiment score.

Company	Overall Sentiment
Burning Rock Biotech	Neutral
Eliem Therapeutics	Neutral

Summary

Burning Rock Biotech beats Eliem Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Burning Rock Biotech compare to DiaMedica Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

DiaMedica Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 77.65%. Given DiaMedica Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe DiaMedica Therapeutics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

DiaMedica Therapeutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market.

Burning Rock Biotech has higher revenue and earnings than DiaMedica Therapeutics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
Burning Rock Biotech	$77.16M	1.40	-$7.92M	-$0.82	N/A

In the previous week, DiaMedica Therapeutics had 3 more articles in the media than Burning Rock Biotech. MarketBeat recorded 3 mentions for DiaMedica Therapeutics and 0 mentions for Burning Rock Biotech. DiaMedica Therapeutics' average media sentiment score of 0.95 beat Burning Rock Biotech's score of 0.00 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
DiaMedica Therapeutics	Positive
Burning Rock Biotech	Neutral

DiaMedica Therapeutics has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -11.57%. Burning Rock Biotech's return on equity of -10.98% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
Burning Rock Biotech	-11.57%	-10.98%	-7.33%

Summary

DiaMedica Therapeutics beats Burning Rock Biotech on 8 of the 15 factors compared between the two stocks.

Get Burning Rock Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNR vs. The Competition

Export

Metric	Burning Rock Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$113.72M	$3.71B	$7.03B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-13.18	9.06	269.91	24.87
Price / Sales	1.40	1,278.42	654.69	108.21
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	1.41	17.97	11.40	6.45
Net Income	-$7.92M	-$13.25M	$3.45B	$347.50M
7 Day Performance	15.79%	5.58%	3.66%	3.77%
1 Month Performance	-9.42%	-1.60%	-0.49%	-0.40%
1 Year Performance	50.09%	61.32%	77.51%	23.55%

Burning Rock Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNR Burning Rock Biotech	0.6694 of 5 stars	$10.24 +16.2%	N/A	+29.2%	$113.72M	$77.16M	N/A	1,390	Gap Up
ABEO Abeona Therapeutics	3.0189 of 5 stars	$6.82 +6.7%	$19.00 +178.6%	+15.7%	$364.20M	$5.82M	7.03	90	Upcoming Earnings
IPSC Century Therapeutics	1.2171 of 5 stars	$2.01 +1.5%	$4.75 +136.3%	+294.2%	$357.10M	$109.16M	N/A	170	Upcoming Earnings
AKBA Akebia Therapeutics	2.2834 of 5 stars	$1.33 +1.1%	$4.67 +252.2%	-73.4%	$351.42M	$236.20M	N/A	430	News Coverage Earnings Report Analyst Downgrade Analyst Revision
ELYM Eliem Therapeutics	N/A	$11.81 -0.8%	N/A	+723.5%	$351.37M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNR) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Burning Rock Biotech (BNR) Competitors

BNR vs. ABEO, IPSC, AKBA, ELYM, and DMAC

How does Burning Rock Biotech compare to Abeona Therapeutics?

Summary

How does Burning Rock Biotech compare to Century Therapeutics?

Summary

How does Burning Rock Biotech compare to Akebia Therapeutics?

Summary

How does Burning Rock Biotech compare to Eliem Therapeutics?

Summary

How does Burning Rock Biotech compare to DiaMedica Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR vs. The Competition

Burning Rock Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Burning Rock Biotech (BNR) Competitors

BNR vs. ABEO, IPSC, AKBA, ELYM, and DMAC

How does Burning Rock Biotech compare to Abeona Therapeutics?

Do institutionals & insiders hold more shares of BNR or ABEO?

Do analysts rate BNR or ABEO?

Is BNR or ABEO more profitable?

Which has more risk & volatility, BNR or ABEO?

Does the media refer more to BNR or ABEO?

Which has better valuation & earnings, BNR or ABEO?

Summary

How does Burning Rock Biotech compare to Century Therapeutics?

Which has higher valuation and earnings, BNR or IPSC?

Which has more volatility & risk, BNR or IPSC?

Is BNR or IPSC more profitable?

Does the media refer more to BNR or IPSC?

Do analysts rate BNR or IPSC?

Do insiders & institutionals hold more shares of BNR or IPSC?

Summary

How does Burning Rock Biotech compare to Akebia Therapeutics?

Is BNR or AKBA more profitable?

Which has more risk & volatility, BNR or AKBA?

Does the media refer more to BNR or AKBA?

Do institutionals & insiders hold more shares of BNR or AKBA?

Which has stronger valuation & earnings, BNR or AKBA?

Do analysts rate BNR or AKBA?

Summary

How does Burning Rock Biotech compare to Eliem Therapeutics?

Do analysts prefer BNR or ELYM?

Which has more risk & volatility, BNR or ELYM?

Do institutionals and insiders have more ownership in BNR or ELYM?

Which has stronger earnings & valuation, BNR or ELYM?

Is BNR or ELYM more profitable?

Does the media refer more to BNR or ELYM?

Summary

How does Burning Rock Biotech compare to DiaMedica Therapeutics?

Do analysts prefer DMAC or BNR?

Do institutionals & insiders have more ownership in DMAC or BNR?

Which has more volatility & risk, DMAC or BNR?

Which has stronger earnings & valuation, DMAC or BNR?

Does the media favor DMAC or BNR?

Is DMAC or BNR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR vs. The Competition

Burning Rock Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools